Regencell Bioscience Holdings Limited

NasdaqCM:RGC 株式レポート

時価総額：US$13.5b

Regencell Bioscience Holdings 将来の成長

Future 基準チェック /06

現在、 Regencell Bioscience Holdingsの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長14.4%
収益成長率n/a
将来の株主資本利益率n/a
アナリストカバレッジ

None

最終更新日n/a

今後の成長に関する最新情報

更新なし

Recent updates

新しいナラティブ • Feb 22

Regencell Bioscience Holdings Ltd. (RGC) The TCM Biotech Lottery Ticket: High Hopes and Extreme Volatility

If you're looking for a stock that perfectly embodies the wild, speculative side of the market for your viewers, Regencell Bioscience (RGC) is it. As of late February 2026, this Hong Kong-headquartered, early-stage bioscience company is trading around $29.17 , following a period of mind-bending volatility where the stock surged thousands of percent over the past year.
Seeking Alpha • Dec 05

Regencell Bioscience: Material Weaknesses Add To Woes

Summary Regencell Bioscience remains severely overvalued at a $6 billion market cap, despite having no revenue, assets, or business activity. RGC's 20-F filing revealed three material weaknesses in internal controls, which raise red flags. There's no clear path to achieving meme stock potential and no clear explanation for the recent price spike. Read the full article on Seeking Alpha
Seeking Alpha • Aug 16

Slow And Steady Wins The Race With Regencell Bioscience

Regencell Bioscience is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine. Regencell Chairman and CEO, Yat-Gai Au recently purchased more than $5.9 million in RGC shares. Majority shareholders of Regencell are insider investors. Regencell is comfortably poised amidst turbulent market conditions, especially for a biotech stock. The company has a list of successful clinical trials, with more to come in the year. Investors from all corners of the market are shrieking to shield their portfolios against a looming recession that's looking to threaten the market as major league stocks have performed poorly over the last couple of months. With the Fed's aggressive rate hike policy as an arsenal to dampen soaring inflation, which hit another fresh high of 9.1% in June, investors are seeking some form of continuity and security in the stock market as conditions only become more choppy. It's been a tumultuous season so far, and value investors who bought in May and went away are perhaps now jumping to get a hand back on their portfolios. Although conditions aren't favorable, some sectors have been receiving growing interest from investors in the last few months as inflation, and rising interest rates are hurting companies' bottom line performance. So while experts and investors are split over the shaky economic conditions, where are they looking now to find a safe haven that can prove to deliver on its performance and return on investment? Is Biotech The Solution Many Are Looking For? Biotech and bioscience stocks have seen a bumpy start to the year, with companies experiencing major stock sell-offs as tourist investors dumped their stocks as interest and hype surrounding the pandemic started winding down. As investors with no interest or knowledge of biotech left the market, it caused a dramatic drop in prices. The biotechnology sector has now become a hunting ground for hedge funds on the lookout for bargain stocks, and some have already scooped up stocks or even launched portfolios to capitalize on the turbulence. There's been a lot of up and down in the biotech market, but some are proving strong and steady against a backdrop of immense economic uncertainty. What's Your Slow And Steady? As investors are on the lookout for cheap biotech stocks which may have great potential upside, the slow and steady performance of some companies may present viable financial returns in the coming years. One company of interest in this specific category is Regencell Bioscience Holdings Limited (RGC), an early-stage bioscience company focusing on the research, development, and commercialization of Traditional Chinese Medicine ("TCM"). Regencell Bioscience focuses on the research and development of neurocognitive disorders and degeneration, more specifically in ADHD, ASD, and infectious diseases such as COVID-19. The bioscience company went public with around 2.6 million ordinary shares at $9.50 per share, raising approximately $22.7 million. RGC has kept investors interested and has received media attention for all the right reasons; the most recent - the company's chairman and CEO, Yat-Gai Au used over $5.9 million of his personal funds to purchase ordinary RGC shares through the open market to support the growth and potential of the company. Sizable stock purchases by insider investors, with the CEO being an exception, have helped the company sidestep short sellers and hedge fund managers that have been taking advantage of small-time investors. Currently, the company has just over 2.6 million shares on the market available for trade. Why Does RGC Make Sense, For Now At Least? RGC is not ordinary, and in many ways, we can see why investors have started noticing the company. So far, year-to-date share prices have increased by 17.03% while the Nasdaq Biotechnology Index has only gone up by 2.69%. On average, share prices are zig-zagging between $34.79 and $35.84, and some investors have set up their year range closer to $59.00 per share. For the six months between July 2021 and December 2021, the company reported a basic diluted loss per share of $0.29, compared to $0.03 for the same period of 2020. The loss could be attributed to the company's sudden increase in operating expenses, which jumped from $368,465 for the 6 months ending December 31, 2020, to $3,658,906 for the same period in 2021, an increase of roughly 893%. The company reported cash availability of $19 million in December 2021, compared to $0.06 million in June 2021. The main source of cash came from net proceeds of the company's IPO, including proceeds from the sales of over-allotment shares, totaling approximately 22.7 million. Initially, when the company went public back in July 2021, share prices were well below their current levels, and a month later, in August 2021, share prices jumped as much as 204% in a single trading session. Since going public, Regencell has treated more than 88 COVID patients with over 94% effectiveness in eliminating symptoms within 6 days; they have ongoing ADHD/ASD clinical studies and were included in the MSCI world microcap index. RGC was also one of the top best-performing stocks on Nasdaq in 2021, according to www.stockanalysis.com. Late last year, Regencell entered preliminary trials for ADHD/ASD. During this time, the stock was trading in the low $20's range. By mid-February 2022, share prices had climbed over $40 before scaling down to the $20's range. Although market conditions have been volatile and investor sentiment negative, RGC has performed quite well since April 2022, with share prices making a swing above $30. The recovery of the stock performance comes from positive clinical results related to the company's RGC-COV19 TCM formula. From our view, we can expect RGC to see another price swing in the coming months when the company announces a second clinical study of a standardized TCM formula for the treatment of ADHD and ASD. Regencell has been working to establish an industry benchmark for treatment, dosing, adverse effects, and measuring patient response. The promising track record and positive clinical results have kept investors interested as RGC has remained relatively stable and resolute in its performance. For investors who can digest small purchases a lot better, RGC could outpace sluggish market conditions. RGC Offers Stability One of the leading reasons or factors that have made RGC stable is its unique ownership structure. Currently, individual insiders possess over 81% of the company's shares, a majority that stands to benefit the most from the stock's relatively good performance so far. On the one hand, RGC is mostly owned by founder and CEO Yat-Gai Au, who is the largest shareholder with an 81% stake. On the other side of the coin, the remaining shareholders own roughly 19% of RGC stock. If we had to look at the most recent data, currently, insider owners own at least $430 million of the $416 million business. When studying these circumstances can act as an indication to investors that the majority of owners are executives, managers, and leaders all within the company. Both general public ownership (11.2%) and private equity ownership (7.6%) are still substantial, and it gives them some power to influence company decisions on performance and growth. Yet, while large enough to play a role, it's not big enough to change company policy. As most of the power is vested and held within the company, it gives them better control over the decision-making and their path towards growth. So for investors who are looking to make a jump at RGC, there's a bit more stability and certainty in its current practice, seeing as board members are investing alongside casual investors.

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Regencell Bioscience Holdings は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

NasdaqCM:RGC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2025N/A-7-4-4N/A
9/30/2025N/A-5-4-4N/A
6/30/2025N/A-4-3-3N/A
3/31/2025N/A-4N/AN/AN/A
12/31/2024N/A-4N/AN/AN/A
9/30/2024N/A-4N/AN/AN/A
6/30/2024N/A-4-4-4N/A
3/31/2024N/A-5N/AN/AN/A
12/31/2023N/A-5N/AN/AN/A
9/30/2023N/A-5N/AN/AN/A
6/30/2023N/A-6-5-5N/A
3/31/2023N/A-6N/AN/AN/A
12/31/2022N/A-7N/AN/AN/A
9/30/2022N/A-7N/AN/AN/A
6/30/2022N/A-7-6-5N/A
3/31/2022N/A-6N/AN/AN/A
12/31/2021N/A-5N/AN/AN/A
9/30/2021N/A-3N/AN/AN/A
6/30/2021N/A-1-1-1N/A
3/31/2021N/A-1N/AN/AN/A
12/31/2020N/A-1-1-1N/A
9/30/2020N/A-1-1-1N/A
6/30/2020N/A-1-1-1N/A

アナリストによる今後の成長予測

収入対貯蓄率: RGCの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: RGCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: RGCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: RGCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: RGCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: RGCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/21 08:25
終値2026/05/21 00:00
収益2025/12/31
年間収益2025/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Regencell Bioscience Holdings Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0